Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects.
Journal
European journal of drug metabolism and pharmacokinetics
ISSN: 2107-0180
Titre abrégé: Eur J Drug Metab Pharmacokinet
Pays: France
ID NLM: 7608491
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
1
6
2020
medline:
3
7
2021
entrez:
1
6
2020
Statut:
ppublish
Résumé
Dabigatran etexilate is a non-vitamin K antagonist oral anticoagulant (NOAC) that is used to prevent stroke and systemic embolism in adults with nonvalvular atrial fibrillation (NVAF) and one or more risk factors. Pharmacokinetic data on this anticoagulant in Chinese subjects are limited. This study aimed to provide further information on the pharmacokinetic profile of dabigatran in healthy Chinese subjects, together with its safety profile. This was an open-label, single-centre, phase I study. Subjects were randomized into 110 and 150 mg dabigatran etexilate treatment groups. Each subject received 7 days of treatment: a single dose on day 1, no dose on days 2-3, and then multiple doses on days 4-10. Blood samples were collected to analyze the pharmacokinetic profile of dabigatran. All adverse events (AEs) were recorded. Routine clinical laboratory tests, a physical examination, vital signs, and 12-lead electrocardiogram (ECG) measurements were performed. A total of 28 subjects (14 males and 14 females) were randomized in this trial. The plasma concentration of total dabigatran reached its maximum measured concentration at a median time of 3-4 h from the dose of interest (either the initial single dose on day 1 or the final dose on day 10) under fed conditions, and declined with an elimination half-life of 10.7-10.9 h following the dose of interest. There was a modest difference in pharmacokinetic profile between male and female subjects. None of the subjects experienced a serious adverse event (SAE) or an AE of moderate or severe intensity. The investigator reported that 17 of the 28 subjects had mild treatment-emergent AEs that resolved without any concomitant treatment or intervention. No clinically significant changes in vital signs or ECG parameters were observed. This study revealed the pharmacokinetic characteristics and good safety profile of dabigatran in healthy Chinese subjects.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Dabigatran etexilate is a non-vitamin K antagonist oral anticoagulant (NOAC) that is used to prevent stroke and systemic embolism in adults with nonvalvular atrial fibrillation (NVAF) and one or more risk factors. Pharmacokinetic data on this anticoagulant in Chinese subjects are limited. This study aimed to provide further information on the pharmacokinetic profile of dabigatran in healthy Chinese subjects, together with its safety profile.
METHODS
METHODS
This was an open-label, single-centre, phase I study. Subjects were randomized into 110 and 150 mg dabigatran etexilate treatment groups. Each subject received 7 days of treatment: a single dose on day 1, no dose on days 2-3, and then multiple doses on days 4-10. Blood samples were collected to analyze the pharmacokinetic profile of dabigatran. All adverse events (AEs) were recorded. Routine clinical laboratory tests, a physical examination, vital signs, and 12-lead electrocardiogram (ECG) measurements were performed.
RESULTS
RESULTS
A total of 28 subjects (14 males and 14 females) were randomized in this trial. The plasma concentration of total dabigatran reached its maximum measured concentration at a median time of 3-4 h from the dose of interest (either the initial single dose on day 1 or the final dose on day 10) under fed conditions, and declined with an elimination half-life of 10.7-10.9 h following the dose of interest. There was a modest difference in pharmacokinetic profile between male and female subjects. None of the subjects experienced a serious adverse event (SAE) or an AE of moderate or severe intensity. The investigator reported that 17 of the 28 subjects had mild treatment-emergent AEs that resolved without any concomitant treatment or intervention. No clinically significant changes in vital signs or ECG parameters were observed.
CONCLUSIONS
CONCLUSIONS
This study revealed the pharmacokinetic characteristics and good safety profile of dabigatran in healthy Chinese subjects.
Identifiants
pubmed: 32474728
doi: 10.1007/s13318-020-00626-4
pii: 10.1007/s13318-020-00626-4
pmc: PMC7511473
doi:
Substances chimiques
Antithrombins
0
Dabigatran
I0VM4M70GC
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
601-609Références
Br J Clin Pharmacol. 2007 Sep;64(3):292-303
pubmed: 17506785
Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S-16S
pubmed: 19696042
Drug Metab Dispos. 2008 Feb;36(2):386-99
pubmed: 18006647
J Med Chem. 2002 Apr 25;45(9):1757-66
pubmed: 11960487
Drugs. 2017 Mar;77(3):331-344
pubmed: 28185082
Thromb Haemost. 2012 Feb;107(2):260-9
pubmed: 22186806
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Lancet. 2002 Feb 16;359(9306):593-603
pubmed: 11867130
West J Emerg Med. 2015 Jan;16(1):11-7
pubmed: 25671002
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
Clin Pharmacokinet. 2008;47(5):285-95
pubmed: 18399711
Eur Heart J. 2012 Nov;33(21):2719-47
pubmed: 22922413
Europace. 2016 Sep;18(9):1308-18
pubmed: 27335063